Lisata Therapeutics, Inc. is a clinical-stage drug discovery and development company focused on a tumor microenvironment-modifying approach to enable more effective treatment of solid tumors. Many solid tumors are surrounded by dense fibrotic tissue, or stroma, which can limit the efficacy of chemotherapies. Additionally, emerging immunotherapy treatments, including checkpoint inhibitors, adoptive cell therapies and RNA-based therapies face challenges in penetrating solid tumors. Lisata’s lead investigational drug, LSTA1 (also known as CEND-1) actuates an active transport system in a tumor-specific manner resulting in systemically co-administered anticancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard of-care chemotherapy for pancreatic cancer. The Company and collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.